On January 12, 2015, the company released new "in vitro" study findings showing that low natural killer cell function associates with greater CFS disease symptom severity, and that rintatolimod treatment increases average NK cell activity over 100%. The new study report, "Low Natural Killer (NK) Activity Observed Across the Chronic Fatigue Syndrome (CFS) Disease Spectrum," has been submitted as a scientific paper for peer review and publication. In addition to the new study findings, the paper summarizes six supportive publications of results with more than 150 CFS patients, correlating increased debility of CFS and low NK cell activity. Clinical testing is currently under way to determine whether NK cell activity augmentation by rintatolimod "in vivo" associates with lessened CFS disease severity and increased physical endurance and performance measures.